. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2019 Aug 13;26(1):26–33. doi: 10.1016/j.bbmt.2019.08.003

Table 3:

Hypogammaglobulinemia

	NHL (N=43)	CLL (N=17)	ALL (N=26)	Entire cohort (N=86)	Ongoing CR (N=21)	Non-ongoing CR (N=65)	P value^#
Hypogammaglobulinemia (IgG < 400 mg/dL or IVIG) pre-lymphodepletion ^{^}	13 (30%)	13 (76%)	8 (31%)	34 (40%)	9 (43%)	25 (38%)	0.80
Late hypogammaglobulinemia (% of patients with available data; N=42) ^*	13/23 (56%)	10/13 (77%)	5/6 (83%)	28/42 (67%)	14/19 (74%)	14/23 (61%)	0.51

^{^}

Last IgG level/IVIG data before lymphodepletion (within 60 days)

Documentations in medical records of IgG level <400 mg/dL and/or IVIG replacement at any time beyond 90 days after CAR-T cell infusion and before subsequent therapy for the underling disease HCT.

P values are for ongoing CR versus non-ongoing CR